myelodysplastic syndromes (MDS) | Page 7 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

First-line Therapeutic Strategies for Myelodysplastic Syndromes.

Author(s): 
Santini V
Primary Author: 
Santini V
Journal Title: 
Clin Lymphoma Myeloma Leuk
Original Publication Date: 
Jul 2017

The precise diagnostic tests and subsequent prognostic stratification for patients with myelodysplastic syndrome (MDS) are often cumbersome, yet they are the basis of successful therapy. Diverse treatment options are available for these patients; however, the decisions in real-life are often not grounded on the available evidence. Although the

Bone Marrow Diseases: 

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

Author(s): 
Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR
Primary Author: 
Unnikrishnan A
Journal Title: 
Cell Rep
Original Publication Date: 
Jul 2017

Bone Marrow Diseases: 

Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

Author(s): 
Press KR, Uy N, Keefer J, Gore SD, Carraway HE, Sakoian S, Prebet T
Primary Author: 
Press KR
Journal Title: 
Leuk Lymphoma
Original Publication Date: 
Jul 2017

No abstract available.

Bone Marrow Diseases: 

Alaskan Goes Home for Treatment and a Fresh Start

Person's Name: 
Shauna McMillan

I tell people I'm unique - almost one of a kind. I am 40 years old and have recently been diagnosed with a rare type of MDS having an unusual deletion 12q cytogenetic abnormality, known MDS 12q (-), or MDS 12q minus.  I was diagnosed in February of 2015 at age 38, however my health struggles began several years before that. I had been living in Alaska for nearly twenty-five years. In 2008, I was diagnosed with lymphocytic colitis (also a rare disease for someone of my age).

Bone Marrow Diseases: 

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

Author(s): 
Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A, Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U
Primary Author: 
Herold S
Journal Title: 
Leukemia
Original Publication Date: 
Jul 2017

No abstract available.

Bone Marrow Diseases: 

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy

Author(s): 
Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J
Primary Author: 
Fenaux P
Journal Title: 
Br J Haematol
Original Publication Date: 
Jun 2017

Romiplostim can improve

Bone Marrow Diseases: 

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

Author(s): 
Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, Slama B, Badre S, Gasal E, Mehta B, Franklin J
Primary Author: 
Platzbecker U
Journal Title: 
Leukemia
Original Publication Date: 
Jun 2017

Use of

Bone Marrow Diseases: 

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Author(s): 
Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Ali NA, Fenaux P, Gore SD, Komrokji R
Primary Author: 
Prebet T
Journal Title: 
Oncotarget
Original Publication Date: 
Jun 2017

While

Bone Marrow Diseases: